EMEloy Muñoz

Eloy Muñoz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eloy Muñoz has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Cell-Based Therapeutic Strategy for Stress Urinary Incontinence: Functional and Molecular Evidence from Decidua-Derived Mesenchymal Stromal Cells

    by Paz de la Torre, Jennifer Collado, Mª José Morán-Jiménez, Laura Forcén, Ana R. Masero-Casasola, Alicia García, Mª Carmen Gutiérrez-Vélez, José Medina-Polo, Eloy Muñoz, José Joaquín Merino, et al.

    Stress urinary incontinence (SUI) is a highly prevalent condition associated with pelvic floor damage, fibroblast dysfunction, and impaired extracellular matrix (ECM) remodeling. This study aimed to investigate the regenerative potential and underlying molecular mechanisms of decidua-derived mesenchymal stromal cells (DMSCs) in a rat model of vaginal distension (VD) and in human suburethral fibroblasts from SUI patients. Adult female rats were subjected to VD and treated with periurethral DMSC injections, followed by functional and transcriptomic analyses, one and six weeks after VD. In parallel, an in vitro co-culture system was used to evaluate the paracrine effects of DMSCs on SUI fibroblasts. DMSC treatment significantly increased leak point pressure (LPP) one week after VD, approaching values observed in control animals (19.8 ± 0.45 vs. 22.3 ± 2.08 mmHg, p = 0.09), while promoting transcriptional changes consistent with tissue repair. Gene expression analyses revealed transient increases in proliferative and inflammatory markers, followed by earlier normalization compared to untreated animals. In vitro, DMSCs reduced p16 expression, increased p21 and Klotho levels, and rebalanced ECM remodeling by decreasing MMP-1 and increasing MMP-2. These findings indicate that DMSCs promote a regenerative microenvironment by modulating senescence and ECM dynamics. Overall, DMSCs may represent a promising disease-modifying strategy for SUI by enhancing tissue repair and functional recovery.

  • Open Access

    A Cell-Based Therapeutic Strategy for Stress Urinary Incontinence: Functional and Molecular Evidence from Decidua-Derived Mesenchymal Stromal Cells

    by Paz de la Torre, Jennifer Collado, María José Morán-Jiménez, Laura Forcén, Ana R. Masero-Casasola, Alicia García, M. Carmen Gutiérrez-Vélez, José Medina-Polo, Eloy Muñoz, José Joaquín Merino, et al.

    Stress urinary incontinence (SUI) is a highly prevalent condition associated with pelvic floor damage, fibroblast dysfunction, and impaired extracellular matrix (ECM) remodeling. This study aimed to investigate the regenerative potential and underlying molecular mechanisms of decidua-derived mesenchymal stromal cells (DMSCs) in a rat model of vaginal distension (VD) and in human suburethral fibroblasts from SUI patients. Adult female rats were subjected to VD and treated with periurethral DMSC injections, followed by functional and transcriptomic analyses, one and six weeks after VD. In parallel, an in vitro co-culture system was used to evaluate the paracrine effects of DMSCs on SUI fibroblasts. DMSC treatment demonstrated a substantial improvement in continence in rats, as measured by leak point pressure (LPP) and accelerated recovery, while modulating key pathways associated with tissue repair. Gene expression analyses revealed transient increases in proliferative and inflammatory markers, followed by earlier normalization compared to untreated animals. In vitro, DMSCs reduced p16 expression, increased p21 and Klotho levels, and rebalanced eECM remodeling by decreasing MMP-1 and increasing MMP-2. These findings indicate that DMSCs promote a regenerative microenvironment by modulating senescence and ECM dynamics. Overall, DMSCs may represent a promising disease-modifying strategy for SUI by enhancing tissue repair and functional recovery.

  • Open Access

    Birth defects in a cohort of infants born to HIV-infected women in Spain, 2000-2009

    by The Madrid Cohort Of Hiv-Infected Mother-Infant Pairs, Luis M Prieto, María Isabel González- Tomé, Eloy Muñoz, María Fernández-Ibieta, Beatriz Soto, Ana Álvarez, Maria Luisa Navarro, Miguel Ángel Roa, José Beceiro, et al.

    Antiretroviral therapy (ART) in pregnancy has resulted in a marked impact on reducing the risk of mother-to-child transmission (MCT) of HIV. However the safety of in utero ART exposure in newborns remains a concern. A multicenter prospective observational study of HIV-infected mother and their infants was performed in Madrid, Spain, from 2000 to 2009. Children had regular visits with clinical examination according to protocol until the age of 24 months. An abdominal ultrasound and an echocardiogram were scheduled during follow up. Birth defects (BDs) were registered according to European Surveillance of Congenital Anomalies (EUROCAT). A total of 897 live births from 872 mothers were included. Overall the birth defects prevalence observed was 6.9% (95% CI 5.4-9.1).The most commonly reported birth defects types were in genital organs and urinary system (19 cases, 30.6%) and cardiovascular system (17 cases, 27.4%). There was no increased risk for infants exposed in the first trimester to ARVs compared with unexposed infants. No significant associations were observed between exposure to any individual antiretroviral agent during pregnancy and birth defects A higher prevalence of BDs was observed, higher than previously reported. In utero exposure to ART was not proved to be a major risk factor of birth defects in infants. However the relatively small number of patients is a major limitation of this study.